Last reviewed · How we verify
QLS-101ophthalmic solution 1% — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
QLS-101ophthalmic solution 1% (QLS-101ophthalmic solution 1%) — Qlaris Bio, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| QLS-101ophthalmic solution 1% TARGET | QLS-101ophthalmic solution 1% | Qlaris Bio, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- QLS-101ophthalmic solution 1% CI watch — RSS
- QLS-101ophthalmic solution 1% CI watch — Atom
- QLS-101ophthalmic solution 1% CI watch — JSON
- QLS-101ophthalmic solution 1% alone — RSS
Cite this brief
Drug Landscape (2026). QLS-101ophthalmic solution 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/qls-101ophthalmic-solution-1. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing